Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Darleen A. Sandoval, David A. D’Alessio
Physiological Reviews (2015) Vol. 95, Iss. 2, pp. 513-548
Closed Access | Times Cited: 414

Showing 1-25 of 414 citing articles:

Glucagon-like peptide 1 (GLP-1)
Timo D. Müller, Brian Finan, Stephen R. Bloom, et al.
Molecular Metabolism (2019) Vol. 30, pp. 72-130
Open Access | Times Cited: 1289
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Fabio Marra, Gianluca Svegliati‐Baroni
Journal of Hepatology (2017) Vol. 68, Iss. 2, pp. 280-295
Closed Access | Times Cited: 689
The Cardiovascular Biology of Glucagon-like Peptide-1
Daniel J. Drucker
Cell Metabolism (2016) Vol. 24, Iss. 1, pp. 15-30
Open Access | Times Cited: 521
Ghrelin, CCK, GLP-1, and PYY(3–36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB
Robert E. Steinert, Christine Feinle‐Bisset, Lori Asarian, et al.
Physiological Reviews (2016) Vol. 97, Iss. 1, pp. 411-463
Open Access | Times Cited: 488
Glucagon-like peptide 1 in health and disease
Andreas Andersen, Asger Lund, Filip K. Knop, et al.
Nature Reviews Endocrinology (2018) Vol. 14, Iss. 7, pp. 390-403
Closed Access | Times Cited: 433
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Antonino Di Pino, Ralph A. DeFronzo
Endocrine Reviews (2019) Vol. 40, Iss. 6, pp. 1447-1467
Open Access | Times Cited: 339
Research progress in the relationship between type 2 diabetes mellitus and intestinal flora
Quantao Ma, Yaqi Li, Pengfei Li, et al.
Biomedicine & Pharmacotherapy (2019) Vol. 117, pp. 109138-109138
Open Access | Times Cited: 336
The New Biology and Pharmacology of Glucagon
Timo D. Müller, Brian Finan, Christoffer Clemmensen, et al.
Physiological Reviews (2017) Vol. 97, Iss. 2, pp. 721-766
Closed Access | Times Cited: 325
Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials
María José Sáez‐Lara, Cándido Robles-Sánchez, Francisco Javier Ruiz‐Ojeda, et al.
International Journal of Molecular Sciences (2016) Vol. 17, Iss. 6, pp. 928-928
Open Access | Times Cited: 290
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Laurie L. Baggio, Daniel J. Drucker
Molecular Metabolism (2020) Vol. 46, pp. 101090-101090
Open Access | Times Cited: 219
The Role of Pancreatic Preproglucagon in Glucose Homeostasis in Mice
Adam P. Chambers, Joyce Sorrell, April Haller, et al.
Cell Metabolism (2017) Vol. 25, Iss. 4, pp. 927-934.e3
Open Access | Times Cited: 197
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
Brent A. McLean, Chi Kin Wong, Jonathan E. Campbell, et al.
Endocrine Reviews (2020) Vol. 42, Iss. 2, pp. 101-132
Open Access | Times Cited: 195
Mechanisms Linking the Gut Microbiome and Glucose Metabolism
Kristina M. Utzschneider, Mario Kratz, Chris Damman, et al.
The Journal of Clinical Endocrinology & Metabolism (2016) Vol. 101, Iss. 4, pp. 1445-1454
Open Access | Times Cited: 188
Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
Maddalena Grieco, Alessandra Giorgi, Maria Cristina Gentile, et al.
Frontiers in Neuroscience (2019) Vol. 13
Open Access | Times Cited: 170
Anti-Obesity Therapy: from Rainbow Pills to Polyagonists
Timo D. Müller, Christoffer Clemmensen, Brian Finan, et al.
Pharmacological Reviews (2018) Vol. 70, Iss. 4, pp. 712-746
Open Access | Times Cited: 162
Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association
Michael E. Hall, Jordana B. Cohen, Jamy D. Ard, et al.
Hypertension (2021) Vol. 78, Iss. 5
Open Access | Times Cited: 146
BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
Tina Zimmermann, Leo Thomas, Tamara Baader-Pagler, et al.
Molecular Metabolism (2022) Vol. 66, pp. 101633-101633
Open Access | Times Cited: 79
Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease
Giovanni Targher, Alessandro Mantovani, Christopher D. Byrne
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 2, pp. 179-191
Open Access | Times Cited: 73
Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report
Michael A. Gulak, Patricia Murphy
Canadian Journal of Anesthesia/Journal canadien d anesthésie (2023) Vol. 70, Iss. 8, pp. 1397-1400
Closed Access | Times Cited: 73
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zhikai Zheng, Zong Yao, Yiyang Ma, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 73
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Rubén Nogueiras, Michael A. Nauck, Matthias H. Tschöp
Nature Metabolism (2023) Vol. 5, Iss. 6, pp. 933-944
Closed Access | Times Cited: 54
The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis
X. Chen, Peiyi Zhao, Weihao Wang, et al.
American Journal of Geriatric Psychiatry (2023) Vol. 32, Iss. 1, pp. 117-127
Closed Access | Times Cited: 53
The microbial metabolite agmatine acts as an FXR agonist to promote polycystic ovary syndrome in female mice
Chuyu Yun, Sen Yan, Baoying Liao, et al.
Nature Metabolism (2024) Vol. 6, Iss. 5, pp. 947-962
Closed Access | Times Cited: 22
Prohormone cleavage prediction uncovers a non-incretin anti-obesity peptide
Laetitia Coassolo, Niels Banhos Danneskiold‐Samsøe, Quennie Nguyen, et al.
Nature (2025)
Closed Access | Times Cited: 2
Preproglucagon Neurons in the Nucleus of the Solitary Tract Are the Main Source of Brain GLP-1, Mediate Stress-Induced Hypophagia, and Limit Unusually Large Intakes of Food
Marie K. Holt, James E. Richards, Daniel R. Cook, et al.
Diabetes (2018) Vol. 68, Iss. 1, pp. 21-33
Open Access | Times Cited: 159
Page 1 - Next Page

Scroll to top